AstraZeneca Signs US$18.5 B Licensing Pact with CSPC Pharmaceutical Group for Obesity and Type 2 Diabetes Treatments

By Naini Anand

Pharma Deals Review: Vol 2026 Issue 2 (Table of Contents)

Published: 12 Feb-2026

DOI: 10.3833/pdr.v2026.i2.2998     ISSN: 1756-7874

Section: Research & Development

Fulltext:

Abstract

AstraZeneca has entered a global collaboration and license agreement with CSPC Pharmaceutical Group, securing exclusive ex-China rights to the latter’s once‑monthly injectable weight‑management portfolio...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details